Exelixis Inc. buy Quitte
Start price
01.03.16
/
50%
€3.78
Target price
25.04.16
€4.21
Performance (%)
11.80%
End price
25.04.16
€4.23
Summary
This prediction ended on 25.04.16 with a price of €4.23. The prediction had a final performance of 11.80%. Quitte has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Exelixis Inc. | 4.847% | 4.847% | 30.668% | 163.916% |
| iShares Core DAX® | -1.358% | -2.329% | 3.438% | 53.509% |
| iShares Nasdaq 100 | -3.700% | -1.242% | 33.079% | 90.966% |
| iShares Nikkei 225® | -2.512% | 6.914% | 60.778% | 81.100% |
| iShares S&P 500 | -1.662% | -0.643% | 23.467% | 67.066% |
Comments by Quitte for this prediction
In the thread Exelixis Inc. diskutieren
gute Zahlen
Exelixis, Inc. (NASDAQ:EXEL) announced its quarterly earnings results on Monday. The biotechnology company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.03, MarketBeat reports. The company had revenue of $9.94 million for the quarter, compared to analyst estimates of $8.16 million. Exelixis’s revenue for the quarter was up 35.2% on a year-over-year basis. During the same period in the prior year, the business posted ($0.30) earnings per share.